This article has Open Peer Review reports available.
The co-presence of deletion 7q, 20q and inversion 16 in therapy-related acute myeloid leukemia developed secondary to treatment of breast cancer with cyclophosphamide, doxorubicin, and radiotherapy: a case report
© Yonal et al; licensee BioMed Central Ltd. 2012
Received: 19 October 2011
Accepted: 16 February 2012
Published: 16 February 2012
Therapy-related acute myeloid leukemia occurs as a complication of treatment with chemotherapy, radiotherapy, immunosuppressive agents or exposure to environmental carcinogens.
We report a case of therapy-related acute myeloid leukemia in a 37-year-old Turkish woman in complete remission from breast cancer. Our patient presented to our facility with fatigue, fever, sore throat, peripheral lymphadenopathy, and moderate hepatosplenomegaly. On peripheral blood and bone marrow aspirate smears, monoblasts were present. Immunophenotypic analysis of the bone marrow showed expression of CD11b, CD13, CD14, CD15, CD33, CD34, CD45 and human leukocyte antigen-DR, findings compatible with the diagnosis of acute monoblastic leukemia (French-American-British classification M5a). Therapy-related acute myeloid leukemia developed three years after adjuvant chemotherapy consisting of an alkylating agent, cyclophosphamide and DNA topoisomerase II inhibitor, doxorubicin and adjuvant radiotherapy. Cytogenetic analysis revealed a 46, XX, deletion 7 (q22q34), deletion 20 (q11.2q13.1) karyotype in five out of 20 metaphases and inversion 16 was detected by fluorescence in situ hybridization. There was no response to chemotherapy (cytarabine and idarubicin, FLAG-IDA protocol, azacitidine) and our patient died in the 11th month after diagnosis.
The median survival in therapy-related acute myeloid leukemia is shorter compared to de novo acute myeloid leukemia. Also, the response to therapy is poor. In therapy-related acute myeloid leukemia, complex karyotypes have been associated with abnormalities of chromosome 5, rather than 7. To the best of our knowledge, this is the first case of therapy-related acute myeloid leukemia showing the co-presence of deletion 7q, 20q and the inversion 16 signal.
Therapy-related acute myeloid leukemias (t-AML) are long-term adverse consequences in malignant diseases treated with chemotherapy, radiation therapy or immunosuppressive agents . The commonest subtype of t-AML develops after exposure to alkylating agents. Most cases present with monosomy/deletion of chromosome 5q and/or monosomy/deletion of 7q [2, 3]. The majority of alkylating agents and radiotherapy treatments damage DNA by methylation . Balanced translocations involving chromosome bands 11q23 and 21q22 may develop following therapy with DNA topoisomerase II inhibitors . Inversion 16 (inv(16)) is one of the less frequent genetic alterations observed after exposure to DNA topoisomerase II inhibitors . In the Chicago University series of 386 patients with therapy-related myelodysplastic syndrome (t-MDS) and t-AML, only eight (2%) patients had abnormalities of -Y, +11, del(11q), del(20q), +21 . Qian et al. reported that complex karyotypes in primary MDS, AML de novo, or t-MDS/t-AML were associated with abnormalities of chromosome 5, rather than chromosome 7 . Here, we report a case of t-AML developed after adjuvant chemoradiotherapy for breast cancer. Cytogenetic analysis revealed abnormalities of both chromosomes 7 and 20 (del(7q) and del(20q)). Fluorescence in situ hybridization (FISH) analysis revealed the inv(16) signal.
The World Health Organization (WHO) classification of therapy-related myeloid neoplasms (t-MN) includes t-AML, t-MDS, or myelodysplastic syndrome/myeloproliferative neoplasms (t-MDS/MPN) that develop secondary to exposure to cytotoxic agents or radiation . The median survival is shorter compared to de novo AML, MDS, or MDS/MPN. Also, the response to therapy is poor. In our patient's case, remission was never achieved. The latency period between first exposure to a cytotoxic agent and the development of t-MN ranges from one to 10 years. t-MN occurs five to seven years after exposure to alkylating agents and radiotherapy [8, 9]. This period was one to three years after the use of DNA topoisomerase II inhibitors [10, 11]. Our patient presented to our facility in a leukemic state three years after exposure to chemoradiotherapy.
t-MN has been reported after chemotherapy with alkylating agents and/or topoisomerase inhibitors for the treatment of Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, breast cancer, ovarian carcinoma, or testicular carcinoma [12–16]. Among solid tumors, breast cancer is the one most commonly associated with an increased risk of development of t-MN.
Taking into consideration the increase in survival and overall cure rate of patients with cancer, the potential risk of therapy-associated secondary malignancies is of growing interest. Nowadays, this issue is becoming particularly important as a significant number of patients with breast cancer receive adjuvant chemotherapy following complete surgical resection. Adjuvant chemotherapy improves survival among women with high-risk breast cancers . The late side effects related to chemotherapy in this particular group of patients need to be clearly elucidated. Certain cytotoxic drugs increase the risk of developing a secondary malignancy. Specifically, t-MN can develop after treatment with alkylating agents and topoisomerase II reactive drugs. Treatment for breast cancer is associated with a 1% to 5% lifetime risk of t-MN. Praga et al. analyzed 9796 patients with breast cancer treated in 19 randomized trials. The cumulative eight-year risk of t-AML was reported as 0.55% . The risk of t-MN increased with higher cumulative doses of both alkylating agents and anthracyclines . Martin et al. reported that younger age at the time of diagnosis, advanced stage disease with distal involvement and radiotherapy were significant risk factors for t-MN in patients with breast cancer . In our patient, who received standard-dose chemotherapy, the identified risk factors for t-AML were young age at the time of diagnosis and radiotherapy.
Alkylating agents have been shown to affect tissue DNA methylation profile . Radiation is also able to induce a stable DNA hypomethylation in both target and bystander tissues. t-MN following ionizing radiations can be assimilated to leukemias following alkylating agents. Voso et al. demonstrated the correlation between p15 methylation and monosomy/deletion of chromosome 7q, proposing it as a relevant event in alkylating-agent-induced leukemogenesis . In alkylating-agent-induced t-MN, 60% to 90% of patients present with monosomy/deletion of 5q and/or monosomy/deletion of 7q . The first subgroup includes cases of t-MN with monosomy/deletion of 5q, with or without abnormalities of chromosome 7. Such cases often present monosomy of chromosome 17 or deletion or loss of 17p, duplication or amplification of chromosome band 11q23, and a complex karyotype with many unidentified abnormalities. The second subgroup of t-MN includes cases with monosomy/deletion of 7q, but normal chromosome 5. Qian et al. reported cytogenetic pattern of 3444 patients with primary MDS, AML de novo, or t-MN. They found that 16% of patients had del(5q), and 17.3% had del(7q). Complex karyotypes were associated with abnormalities of chromosome 5, rather than 7. Recurring abnormalities observed at a high frequency (> 20%) in patients with del(5q) included +8, and loss of 13q, 16q, 17p (40% of cases), chromosome 18, and 20q . In our patient, however, other genetic abnormalities (del 20q and the inv(16)) were present in addition to the chromosomal abnormality on chromosome 7.
The latency between the alkylating agents and t-MN is between five and seven years. This group often exhibits a M1 or M2 phenotype (FAB classification). Generally, overt leukemia develops following a dysplastic phase. t-MN related to alkylating agents typically has a poor prognosis .
Chromosomal breakage induced by DNA topoisomerase II inhibitors is responsible for its antineoplastic and leukemogenic effects, and this breakage resolved by chromosomal translocation is the cause of the leukemic transformation . t-MN after DNA topoisomerase II inhibitors typically has a short latency time, ranging between one and three years from primary treatment [4, 15]. Among the genetic derangements associated with DNA topoisomerase II inhibitors, translocations at the long arm of chromosome 11 (11q23) are the most followed by t(8;21), t(3;21), t(16;21), t(17;21), inv(16), t(8;16) and t(9;22) . DNA topoisomerase II inhibitor-related t-AML most commonly presents with M4 or M5 morphological type and is not associated with MDS. We present a case with M5 morphological type. Pedersen-Bjergaard et al. were the first to report the presence of inv(16)(p13q22) as a single chromosomal abnormality in t-AML treated with radiotherapy and subsequently with MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) in a patient with Hodgkin's disease . In our patient with AC chemotherapy-related AML, inv(16)(p13q22) was one of the three chromosomal abnormalities observed.
In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B25 trial of adjuvant AC chemotherapy for breast cancer, six out of 2534 cases in the high-dose cyclophosphamide/high-dose doxorubicin treatment arm developed M4 or M5 AML, with three patients exhibiting 11q23 abnormalities. Topoisomerase II was accounted for development of leukemia in these patients. Ten other patients developed AML or MDS, with three patients exhibiting M1 or M2 morphology and five patients showing typical alkylating-agent-induced abnormalities of chromosomes 5 or 7 . To the best of our knowledge, our patient's case is the first case of t-AML showing M5 morphology with del 7q, 20q and the inv(16) signal developed three years after chemoradiotherapy for breast cancer.
With recent developments and improved cure rates in cancer therapy, t-MN is an increasingly recognized obstacle. Patients must be informed about the potential risk of developing t-MN following chemotherapy.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We would like to thank the Cytogenetics Laboratory at Istanbul University, Istanbul Medical Faculty, for assistance with sample processing.
- Voso MT, D'Alò F, Greco M, Fabiani E, Criscuolo M, Migliara G, Pagano L, Fianchi L, Guidi F, Hohaus S, Leone G: Epigenetic changes in therapy-related MDS/AML. Chem Biol Interact. 2010, 184: 46-49. 10.1016/j.cbi.2009.10.013.View ArticlePubMedGoogle Scholar
- Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK: Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2006, 20: 1943-1949. 10.1038/sj.leu.2404381.View ArticlePubMedGoogle Scholar
- Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH: Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008, 22: 240-248. 10.1038/sj.leu.2405078.View ArticlePubMedGoogle Scholar
- Leone G, Fianchi L, Pagano L, Voso MT: Incidence and susceptibility to therapy related myeloid neoplasms. Chem Biol Interact. 2010, 184: 39-45. 10.1016/j.cbi.2009.12.013.View ArticlePubMedGoogle Scholar
- Qian Z, Joslin JM, Tennant TR, Reshmi SC, Young DJ, Stoddart A, Larson RA, Le Beau MM: Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact. 2010, 184: 50-57. 10.1016/j.cbi.2009.11.025.View ArticlePubMedGoogle Scholar
- Mitelman F: ISCN: An International System for Human Cytogenetic Nomenclature. 1995, Basel, Switzerland: S KargerGoogle Scholar
- World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Edited by: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008, Lyon, France: IARC PressGoogle Scholar
- Rowley JD, Golomb HM, Vardiman JW: Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood. 1981, 58: 759-PubMedGoogle Scholar
- Gundestrup M, Klarskov Andersen M, Sveinbjornsdottir E, Rafnsson V, Storm HH, Pedersen-Bjergaard J: Cytogenetics of myelodysplasia and acute myeloid leukaemia in aircrew and people treated with radiotherapy. Lancet. 2000, 356: 2158-10.1016/S0140-6736(00)03501-7.View ArticlePubMedGoogle Scholar
- Ratain MJ, Rowley JD: Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol. 1992, 3: 107-View ArticlePubMedGoogle Scholar
- Pui CH, Relling MV: Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol. 2000, 109: 13-10.1046/j.1365-2141.2000.01843.x.View ArticlePubMedGoogle Scholar
- Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH: Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007, 25: 3871-3876. 10.1200/JCO.2007.12.0832.View ArticlePubMedGoogle Scholar
- Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007, 99: 196-205. 10.1093/jnci/djk028.View ArticlePubMedGoogle Scholar
- Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C: Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or highdose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol. 1998, 124: 207-214. 10.1007/s004320050156.View ArticlePubMedGoogle Scholar
- Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P: Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995, 86: 3542-3552.PubMedGoogle Scholar
- Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia- Manero G, Cortes J, Kantarjian H, Ravandi F: Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer. 2009, 115: 101-106. 10.1002/cncr.24005.View ArticlePubMedPubMed CentralGoogle Scholar
- Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717.View ArticleGoogle Scholar
- Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D: Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005, 23: 4179-4191. 10.1200/JCO.2005.05.029.View ArticlePubMedGoogle Scholar
- Martin MG, Welch JS, Luo J, Ellis MJ, Graubert TA, Walter MJ: Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat. 2009, 118: 593-598. 10.1007/s10549-009-0376-3.View ArticlePubMedPubMed CentralGoogle Scholar
- Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L, Henry PH, Romond EH, Lanier KS, Davila E, Kardinal CG, Laufman L, Pierce HI, Abramson N, Keller AM, Hamm JT, Wickerham DL, Begovic M, Tan-Chiu E, Tian W, Wolmark N: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol. 1999, 17: 3374-3388.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.